Fraser Murray, a co-founder of Polleo Pharma Ltd, has joined Chronos Therapeutics Ltd in Oxford, UK as one of two new vice presidents for preclinical development. Chronos is working on new therapeutics for diseases related to ageing. The second executive to join is Timothy Schulz-Utermoehl, also a Polleo co-founder. Drs Murray and Schulz-Utermoehl will be responsible for three preclinical research programmes targeting fatigue in multiple sclerosis, addiction and post-traumatic stress disorder.
Dr Murray was head of discovery biology for Shire Plc before co-founding Polleo with a focus on central nervous system and gastrointestinal disorders. He holds a PhD from the School of Pharmacy at University College London.
Dr Schulz-Utermoehl was a director with the exploratory projects department at Shire before co-founding Polleo. He holds a PhD in biochemistry from Imperial College London and carried out post-doctoral research at Novo Nordisk A/S.
Chronos announced the appointments on 4 August 2016.
Copyright 2016 Evernow Publishing Ltd